Catalyst Pharmaceutical Partners (CPRX) 3.13 $CPRX
DON, EEB, PRFZ, CPRX, RGI, DVR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Sep 10, 3:54AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Donner Metals Ltd (NYSE
ON), Guggenheim BRIC ETF (NYSE:EEB), PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (NASDAQ
RFZ), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Reco International Group Inc (NYSE:RGI), Cal Dive International Inc (NYSE VR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
Catalyst Pharmaceutical (CPRX) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as its shares rose nearly 9% on the day.
Catalyst Pharmaceuticals hires David D. Muth as EVP of Corporate Development
M2 - Fri Sep 05, 6:32AM CDT
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Thursday the addition of David D. Muth as executive vice president of its Corporate Development.
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
GlobeNewswire - Thu Sep 04, 7:26AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst's corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse(TM).
Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 7:08AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw's 16 Annual Global Investment Conference, which is being held on September 8-10, 2014 at The Palace Hotel in New York, NY.
Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
GlobeNewswire - Tue Sep 02, 7:07AM CDT
Brain GABA Levels, a potential surrogate marker of efficacy, will also be followed
Your September Biotech Back-to-School Calendar
at The Street - Tue Aug 26, 8:50AM CDT
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:46AM CDT
Catalyst Pharmaceutical Partners (CPRX) was a big mover last session, with shares rising over 10% on the day.
Catalyst Pharmaceutical Partners Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the second quarter and six months ended June 30, 2014.
Catalyst Pharmaceutical Partners Provides Updates on Progress of Phase 3 Firdapse Study in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Aug 11, 7:05AM CDT
Last Patient Completes 2-Week, Blinded Primary Treatment Period - Top-Line Data on Track to Report in 3Q14
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Global Drug Addiction Clinical Trials Review, H1, 2014 Featuring 20 Top Companies/Institutions
M2 - Tue Jul 01, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3767t/drug_addiction) has announced the addition of the "Drug Addiction Global Clinical Trials Review, H1, 2014" report to their offering. Drug Addiction Global Clinical Trials Review, H1, 2014" provides data on the Drug Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Drug Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Drug Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - RTI International - Johnson & Johnson - Alkermes Inc. (Inactive) - SK Holdings Co., Ltd. - Reckitt Benckiser Group Plc - GlaxoSmithKline plc - Embera NeuroTherapeutics, Inc. - Catalyst Pharmaceutical Partners, Inc. - Gilead Sciences, Inc. - D&A Pharma SAS Clinical Trial Overview of Top Institutes / Government - National Institute on Drug Abuse - Yale University - University of Pennsylvania - New York State Psychiatric Institute - University of California, Los Angeles - Johns Hopkins University - Medical University of South Carolina - Baylor College of Medicine - University of Arkansas - University of Kentucky For more information visit http://www.researchandmarkets.com/research/k3..._addiction
Catalyst Pharmaceutical Partners to Present at the JMP Securities 2014 Healthcare Conference
GlobeNewswire - Thu Jun 19, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 24 at 12:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Catalyst Pharmaceutical Partners Set to Join Russell Microcap(R) Index
GlobeNewswire - Wed Jun 18, 12:03PM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that the Company is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.
Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
M2 - Wed Apr 02, 4:46AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday the completion of patient enrollment under its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a neuromuscular and neurological disease.
Catalyst Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse(TM) in Patients With Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
DON, EEB, PRFZ, CPRX, RGI, DVR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Sep 10, 3:54AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Donner Metals Ltd (NYSE
ON), Guggenheim BRIC ETF (NYSE:EEB), PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (NASDAQ RFZ), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Reco International Group Inc (NYSE:RGI), Cal Dive International Inc (NYSE VR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
Catalyst Pharmaceutical (CPRX) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as its shares rose nearly 9% on the day.
Catalyst Pharmaceuticals hires David D. Muth as EVP of Corporate Development
M2 - Fri Sep 05, 6:32AM CDT
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Thursday the addition of David D. Muth as executive vice president of its Corporate Development.
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
GlobeNewswire - Thu Sep 04, 7:26AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst's corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse(TM).
Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 7:08AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw's 16 Annual Global Investment Conference, which is being held on September 8-10, 2014 at The Palace Hotel in New York, NY.
Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
GlobeNewswire - Tue Sep 02, 7:07AM CDT
Brain GABA Levels, a potential surrogate marker of efficacy, will also be followed
Your September Biotech Back-to-School Calendar
at The Street - Tue Aug 26, 8:50AM CDT
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:46AM CDT
Catalyst Pharmaceutical Partners (CPRX) was a big mover last session, with shares rising over 10% on the day.
Catalyst Pharmaceutical Partners Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the second quarter and six months ended June 30, 2014.
Catalyst Pharmaceutical Partners Provides Updates on Progress of Phase 3 Firdapse Study in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Aug 11, 7:05AM CDT
Last Patient Completes 2-Week, Blinded Primary Treatment Period - Top-Line Data on Track to Report in 3Q14
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Global Drug Addiction Clinical Trials Review, H1, 2014 Featuring 20 Top Companies/Institutions
M2 - Tue Jul 01, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3767t/drug_addiction) has announced the addition of the "Drug Addiction Global Clinical Trials Review, H1, 2014" report to their offering. Drug Addiction Global Clinical Trials Review, H1, 2014" provides data on the Drug Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Drug Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Drug Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - RTI International - Johnson & Johnson - Alkermes Inc. (Inactive) - SK Holdings Co., Ltd. - Reckitt Benckiser Group Plc - GlaxoSmithKline plc - Embera NeuroTherapeutics, Inc. - Catalyst Pharmaceutical Partners, Inc. - Gilead Sciences, Inc. - D&A Pharma SAS Clinical Trial Overview of Top Institutes / Government - National Institute on Drug Abuse - Yale University - University of Pennsylvania - New York State Psychiatric Institute - University of California, Los Angeles - Johns Hopkins University - Medical University of South Carolina - Baylor College of Medicine - University of Arkansas - University of Kentucky For more information visit http://www.researchandmarkets.com/research/k3..._addiction
Catalyst Pharmaceutical Partners to Present at the JMP Securities 2014 Healthcare Conference
GlobeNewswire - Thu Jun 19, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 24 at 12:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Catalyst Pharmaceutical Partners Set to Join Russell Microcap(R) Index
GlobeNewswire - Wed Jun 18, 12:03PM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that the Company is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.
Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
M2 - Wed Apr 02, 4:46AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday the completion of patient enrollment under its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a neuromuscular and neurological disease.
Catalyst Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse(TM) in Patients With Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
